CY1106564T1 - Πολυπεπτιδια δυναμενα αποσπασης μιας ανοσιακης αντιδρασης εναντι του καρκινου - Google Patents

Πολυπεπτιδια δυναμενα αποσπασης μιας ανοσιακης αντιδρασης εναντι του καρκινου

Info

Publication number
CY1106564T1
CY1106564T1 CY20071100601T CY071100601T CY1106564T1 CY 1106564 T1 CY1106564 T1 CY 1106564T1 CY 20071100601 T CY20071100601 T CY 20071100601T CY 071100601 T CY071100601 T CY 071100601T CY 1106564 T1 CY1106564 T1 CY 1106564T1
Authority
CY
Cyprus
Prior art keywords
immune response
response against
triggering
against cancer
polypeptides capable
Prior art date
Application number
CY20071100601T
Other languages
English (en)
Inventor
Gustav Gaudernack
Stein Saeboe-Larssen
Mona Moller
Jon Amund Eriksen
Original Assignee
Gemvax As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9905720&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1106564(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gemvax As filed Critical Gemvax As
Publication of CY1106564T1 publication Critical patent/CY1106564T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με πολυπεπτίδια και με το DNA πυρηνικών οξέων που κωδικοποιεί αυτά τα πολυπεπτίδια, δυνάμενα απόσπασης μιας ανοσιακής αντίδρασης έναντι του καρκίνου, με τις μεθόδους παραγωγής Τ λεμφοκυττάρων δυνάμενων να αναγνωρίσουν και να καταστρέψουν τα καρκινικά κύτταρα και με τις φαρμακευτικές συνθέσεις για την θεραπεία, την προφύλαξη ή την διάγνωση του καρκίνου.
CY20071100601T 2000-12-22 2007-05-07 Πολυπεπτιδια δυναμενα αποσπασης μιας ανοσιακης αντιδρασης εναντι του καρκινου CY1106564T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0031430.2A GB0031430D0 (en) 2000-12-22 2000-12-22 Polypeptides
PCT/NO2001/000498 WO2002051994A2 (en) 2000-12-22 2001-12-18 Polypeptides

Publications (1)

Publication Number Publication Date
CY1106564T1 true CY1106564T1 (el) 2012-01-25

Family

ID=9905720

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20071100601T CY1106564T1 (el) 2000-12-22 2007-05-07 Πολυπεπτιδια δυναμενα αποσπασης μιας ανοσιακης αντιδρασης εναντι του καρκινου
CY20121100447T CY1112735T1 (el) 2000-12-22 2012-05-14 Πολυπεπτιδια δυναμενα εκμαιευσης μιας ανοσιακης αντιδρασης εναντι του καρκινου

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20121100447T CY1112735T1 (el) 2000-12-22 2012-05-14 Πολυπεπτιδια δυναμενα εκμαιευσης μιας ανοσιακης αντιδρασης εναντι του καρκινου

Country Status (14)

Country Link
US (4) US7078416B2 (el)
EP (3) EP1352056B1 (el)
JP (3) JP2004522433A (el)
AT (2) ATE358716T1 (el)
AU (3) AU2002216477B2 (el)
CA (2) CA2432971C (el)
CY (2) CY1106564T1 (el)
DE (1) DE60127715T2 (el)
DK (3) DK2361978T3 (el)
ES (2) ES2382821T3 (el)
GB (1) GB0031430D0 (el)
NO (2) NO332137B1 (el)
PT (2) PT1862544E (el)
WO (1) WO2002051994A2 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
JP2004527449A (ja) * 2000-02-15 2004-09-09 リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア テロメラーゼ逆転写酵素を用いる癌を治療するための万能ワクチンと方法
GB0031430D0 (en) * 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
BR0316758A (pt) * 2002-12-16 2005-10-25 Globeimmune Inc Vacinas baseadas em levedura como imunoterapia
EP2463299A3 (en) * 2003-03-05 2012-10-17 Dendreon Corporation Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
EP1809773B1 (en) * 2004-10-18 2014-07-16 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis c infection
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
EP2331125A4 (en) 2008-09-19 2013-03-27 Globeimmune Inc IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
EP3576764A4 (en) 2017-02-03 2020-12-16 The Medical College of Wisconsin, Inc. KRAS PEPTIDE VACCINE COMPOSITIONS AND METHOD OF USE
WO2018223092A1 (en) 2017-06-02 2018-12-06 Arizona Board Of Regents On Behalf Of Arizona State University A method to create personalized cancer vaccines
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University METHODS AND COMPOSITIONS FOR IDENTIFYING NEOANTIGENS FOR USE IN THE TREATMENT AND PREVENTION OF CANCER

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803070A (en) 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
JP2002514928A (ja) 1997-07-01 2002-05-21 キャンビア バイオシステムス リミティド ライアビリティー カンパニー 脊椎動物テロメラーゼ遺伝子およびタンパク質ならびにその使用
CA2347067C (en) 1998-03-31 2013-09-17 Geron Corporation Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer
WO1999050932A1 (fr) * 1998-03-31 1999-10-07 Matsushita Electric Industrial Co., Ltd. Antenne et televiseur numerique
US6337200B1 (en) * 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
EP1171612A2 (en) * 1999-04-09 2002-01-16 Biomira, Inc. Telomerase-specific cancer vaccine
AU5047800A (en) 1999-05-28 2000-12-18 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
GB0031430D0 (en) * 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides

Also Published As

Publication number Publication date
JP2012080883A (ja) 2012-04-26
US8193326B2 (en) 2012-06-05
DK1862544T3 (da) 2012-07-09
AU2007211889C1 (en) 2010-06-10
EP1862544B2 (en) 2016-03-09
EP2361978A1 (en) 2011-08-31
EP1352056B1 (en) 2007-04-04
AU2002216477C1 (en) 2002-07-08
ATE550426T1 (de) 2012-04-15
GB0031430D0 (en) 2001-02-07
US20060194731A1 (en) 2006-08-31
EP1862544A1 (en) 2007-12-05
JP2014138587A (ja) 2014-07-31
AU2007211889A1 (en) 2007-09-13
ES2382821T3 (es) 2012-06-13
US7078416B2 (en) 2006-07-18
EP1862544B1 (en) 2012-03-21
WO2002051994A8 (en) 2003-03-06
JP2004522433A (ja) 2004-07-29
US20120269858A1 (en) 2012-10-25
US20080187551A1 (en) 2008-08-07
NO20110429L (no) 2003-08-21
ATE358716T1 (de) 2007-04-15
CA2782510A1 (en) 2002-07-04
NO342257B1 (no) 2018-04-30
PT1862544E (pt) 2012-05-07
CA2782510C (en) 2014-07-15
AU2002216477B2 (en) 2007-05-24
US7375117B2 (en) 2008-05-20
DE60127715D1 (de) 2007-05-16
NO20032818L (no) 2003-08-21
WO2002051994A3 (en) 2002-12-27
AU2007211889B8 (en) 2009-12-10
CA2432971C (en) 2012-09-04
EP2361978B1 (en) 2015-10-14
ES2280311T3 (es) 2007-09-16
NO332137B1 (no) 2012-07-02
AU2010200620A1 (en) 2010-03-11
WO2002051994A2 (en) 2002-07-04
DK1352056T3 (da) 2007-05-29
AU2007211889B2 (en) 2009-11-19
CA2432971A1 (en) 2002-07-04
DK2361978T3 (en) 2016-01-25
DE60127715T2 (de) 2007-12-27
NO20032818D0 (no) 2003-06-19
US20040072759A1 (en) 2004-04-15
PT1352056E (pt) 2007-05-31
CY1112735T1 (el) 2016-02-10
EP1352056A2 (en) 2003-10-15
AU2010200620B2 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
CY1106564T1 (el) Πολυπεπτιδια δυναμενα αποσπασης μιας ανοσιακης αντιδρασης εναντι του καρκινου
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1109463T1 (el) Πεπτιδια kdr και εμβολια που τα περιλαμβανουν
TR200806259T2 (tr) Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler
HUP0401591A2 (hu) Új receptor-nukleinsavak és- polipeptidek
EE9900343A (et) Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
DE60035337D1 (de) Humane Peptide/Proteine, die das Töten von Zellen, einschliesslich lymphoide Tumorzellen, herbeiführen oder bewirken
CY1110177T1 (el) Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
DE69929310D1 (de) Tumorassoziierte antigenderivate der mage-familie, nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
DE69940264D1 (de) Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1
WO2002061113A3 (en) Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
CY1112171T1 (el) Μτβ32α αντιγονο μυκοβακτηριδιου της φυματιωσης με απενεργοποιημενη δραστικη θεση και πρωτεϊνες συντηξης αυτου
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
EP1570081A4 (en) AMPLIFIED GENES INVOLVED IN CANCER
HUP0100352A2 (hu) Mycobacterium vaccaeből származó kompozíciók és eljárások ezek alkalmazására
HK1082666A1 (en) Ihnv g fusion protein for immune stimulation
ATE311456T1 (de) Nucleinsäure-moleküle codierend proteine, die die adhäsion von neisseria-zellen an humane zellen vermitteln
CO5650177A2 (es) Constructos geneticos y composiciones que comprenden rre y cte y usos de estos
DK1268522T3 (da) LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
BR9708188A (pt) Imunidade a espécies de tripanosomatidae.
WO2002066652A3 (en) Ehrlichia ruminantium polypeptides, antigens, polynucleotides, and methods of use
WO2002046380A3 (en) Protein kinase